All In Biotech

Drug Trial Radar · NCT04676529

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

43

Actual

Start

Feb 18, 2021

Primary completion

Jul 9, 2025

Study completion Jul 9, 2025

Sponsor

Lead sponsor
SyntaraIndustry
Sponsor type
Industry
First posted
Dec 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be an open-label phase 1/2a study to evaluate the safety and tolerability of PXS-5505 in patients with primary, postpolycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis.

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis (PMF)
  • Post- Essential Thrombocythemia Myelofibrosis
  • Post Polycythemia Vera Myelofibrosis

Interventions

  • PXS-5505Drug

    PXS-5505 is a hard capsule (size 0) with the additional excipients mannitol and magnesium stearate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Serious and Non-serious Adverse EventsTime frame: Day 0 to follow-up visit (28 -1/+7days post-Tx end) after up to 4wks Tx [escalation phase]; Day 0 to follow-up visit (28±3days post-Tx end) after up to 24wks Tx [expansion]); Day 0 to follow-up visit (28± 3days post-Tx end) after up to 52wks Tx [add-on].

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Comprehensive Cancer Center (UAB CCC)

    Birmingham, Alabama

  • Novant Health Cancer Institute

    Winston-Salem, North Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Liverpool Hospital

    Liverpool, New South Wales, Australia

  • Ashford Cancer Centre Research

    Adelaide, South Australia, Australia

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia

  • One Clinical Research

    Perth, Western Australia, Australia

  • The Perth Blood Institute

    West Perth, Western Australia, Australia

  • National Cancer Center (Seoul Metro; northern)

    Gyeonggi-do, South Korea

  • Seoul National University Hospital - Bundang

    Gyeonggi-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University Health System- Haemat

    Seoul, South Korea

  • Asan Medical Centre

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • Inje University Busan Paik Hospital - Internal Medicine

    Busan, Busan Gwang'yeogsi [Pusan-Kwan, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, Daegu Gwang'yeogsi [Taegu-Kwangyokshi], South Korea

  • Gachon University Gil Hospital

    Incheon, Incheon Gwang'yeogsi [Inch'n-K, South Korea

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • China Medical University Hospital - Internal Medicine - Taichung

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • National Taiwan University Hospital - Hematology And Oncology

    Taipei, Taiwan

  • Chang Gung Medical Foundation - ChiaYi Chang Gung Memorial Hospital - Hematology and Oncology

    Chiayi City, Chiayi, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.